Payment overview · 2025
General Payments
$14.13
1 reported records · 1 companies
Healthcare provider profile · identity verified
Wilson Gomer, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SAN BERNARDINO, CA · NPI 1184656928
Verified facts
What the public records show
CMS Open Payments records show Wilson Gomer, MD received $14.13 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Lokelma by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.13 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $14.13 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.13 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 600 | 136 |
| Amlodipine Besylate | Amlodipine Besylate | 465 | 93 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 342 | 65 |
| Furosemide | Furosemide | 338 | 66 |
| Metformin Hcl | Metformin Hcl | 320 | 67 |
| Lisinopril | Lisinopril | 315 | 72 |
| Omeprazole | Omeprazole | 287 | 55 |
| Gabapentin | Gabapentin | 266 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 43 |
| Simvastatin | Simvastatin | 241 | 52 |
| Clonidine Hcl | Clonidine Hcl | 225 | 47 |
| Potassium Chloride | Potassium Chloride | 209 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 200 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 183 | 33 |
| Losartan Potassium | Losartan Potassium | 179 | 45 |
| Tramadol Hcl | Tramadol Hcl | 166 | 40 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 162 | 31 |
| Ibuprofen | Ibuprofen | 148 | 38 |
| Nifedipine Er | Nifedipine | 140 | 25 |
| Carvedilol | Carvedilol | 136 | 28 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 112 | 25 |
| Januvia | Sitagliptin Phosphate | 104 | 17 |
| Ozempic | Semaglutide | 104 | 15 |
| Lorazepam | Lorazepam | 96 | 17 |
| Sertraline Hcl | Sertraline Hcl | 96 | 19 |
| Aripiprazole | Aripiprazole | 93 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 92 | 23 |
| Glipizide | Glipizide | 85 | 18 |
| Fenofibrate | Fenofibrate | 81 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 79 | 18 |
| Benazepril Hcl | Benazepril Hcl | 78 | 18 |
| Enalapril Maleate | Enalapril Maleate | 78 | 18 |
| Memantine Hcl | Memantine Hcl | 77 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 19 |
| Trazodone Hcl | Trazodone Hcl | 76 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 73 | 19 |
| Sumatriptan Succinate | Sumatriptan Succinate | 72 | 11 |
| Megestrol Acetate | Megestrol Acetate | 71 | suppressed |
| Eliquis | Apixaban | 69 | 15 |
| Diazepam | Diazepam | 68 | 11 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Famotidine | Famotidine | 63 | 15 |
| Levetiracetam | Levetiracetam | 63 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | suppressed |
| Alprazolam | Alprazolam | 60 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 59 | suppressed |
| Jardiance | Empagliflozin | 59 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 58 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 57 | 14 |
| Finasteride | Finasteride | 57 | suppressed |
| Methocarbamol | Methocarbamol | 55 | suppressed |
| Cephalexin | Cephalexin | 54 | 30 |
| Donepezil Hcl | Donepezil Hcl | 53 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 52 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 50 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 50 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 49 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 48 | 12 |
| Olanzapine | Olanzapine | 48 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 48 | 11 |
| Latanoprost | Latanoprost | 47 | suppressed |
| Azithromycin | Azithromycin | 46 | 31 |
| Naproxen | Naproxen | 46 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 45 | suppressed |
| Allopurinol | Allopurinol | 43 | 12 |
| Atenolol | Atenolol | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 14 |
| Novolog Flexpen | Insulin Aspart | 40 | 11 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Lactulose | Lactulose | 38 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Topiramate | Topiramate | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 22 |
| Prednisone | Prednisone | 37 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Baclofen | Baclofen | 35 | suppressed |
| Gemfibrozil | Gemfibrozil | 34 | suppressed |
| Mirtazapine | Mirtazapine | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 31 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 27 | suppressed |
| Ezetimibe | Ezetimibe | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Risperidone | Risperidone | 26 | suppressed |
| Trueplus Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 11 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Loperamide | Loperamide Hcl | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 18 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 17 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 15 | suppressed |
| Lumigan | Bimatoprost | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Celecoxib | Celecoxib | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Sure Comfort | Syring-Needl,disp,insul,0.3 Ml | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $14.13 · 1 records | AstraZeneca Pharmaceuticals LP | BREZTRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error